This study also contributed to the conclusion of SGLT-2 inhibitors' beneficence, specifically empagliflozin, in terms of cardiovascular outcomes and mortality in T2DM patients regardless of risk levels (low, medium, or high cardiovascular risk) [9]. Here, SLC5A2 is linked to type 2 diabetes mellitus.